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Aim: To evaluate antitumor effect of plant polyphenol extracts from green tea, red wine lees and/or lemon peel alone and in combina-
tion with antitumor drugs on the growth of different transplanted tumors in experimental animals. Materials and Methods: Green tea 
extract (GTE) was prepared from green tea infusion. GTE-based composites of red wine (GTRW), lemon peel (GTRWL) and/
or NanoGTE as well as corresponding nanocomposites were prepared. The total polyphenolics of the different GTE-based extracts 
ranged from 18.0% to 21.3%. The effects of GTE-based extracts were studied in sarcoma 180, Ehrlich carcinoma, B16 melanoma, 
Ca755 mammary carcinoma, P388 leukemia, L1210 leukemia, and Guerin carcinoma (original, cisplatin-resistant and doxorubicin-
resistant variants). The extracts were administered as 0.1% solution in drinking water (0.6–1.0 mg by total polyphenolics per mouse 
per day and 4.0–6.3 mg per rat per day). Results: Tumor growth inhibition (TGI) in mice treated with NanoGTE, cisplatin or cispla-
tin + NanoGTE was 27%, 55% and 78%, respectively, in Sarcoma 180%, 21%, 45% and 59%, respectively, in Ehrlich carcinoma; 
and 8%, 13% and 38%, respectively in B16 melanoma. Composites of NanoGTE, red wine, and lemon peel (NanoGTRWL) enhanced 
the antitumor effects of cyclophosphamide in mice with Ca755 mammary carcinoma. The treatment with combination of NanoGTE 
and inhibitors of polyamines (PA) synthesis (DFMO + MGBG) resulted in significant TGI of P388 leukemia (up to 71%) and 
L1210 leukemia. In rats transplanted with Guerin carcinoma (parental strain), treatment with GTRW or GTE alone resulted in 25–
28% TGI vs. 55–68% TGI in cisplatin-treated animals. The inhibition observed in the case of combination of GTE or GTRW with 
cisplatin was additive giving 81–88% TGI. Similar effects were observed when combinations of the cytostatics with GTE (or  NanoGTE) 
were tested against cisplatin- or doxorubicin-resistant Guerin carcinoma. Moreover, the plant extracts lowered side toxicity of the 
drugs. Treatment with GTE, NanoGTE, and NanoGTRW decreased the levels of malondialdehyde in heart, kidney and liver tissue 
of experimental animals, as well as the levels of urea and creatinine in blood serum, increased erythrocyte and platelet counts, hemo-
globin content, and decreased leucocyte counts. Conclusion: The obtained data indicate the prospects for further deve lopment of GTE 
and corresponding nanocomposites as auxiliary agents in cancer chemotherapy.
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Cancer is one of the major causes of death 
in Ukraine and in Western countries. Only 5–10% of all 
cancer cases are associated with genetic factors and 
90–95% of cases are influenced by lifestyle, such 
as smoking, diet, alcohol, sedentary lifestyle, obesity 
and sun exposure, as well as infections and environ-
mental contaminants [1, 2]. These results argue that 
there are opportunities to prevent cancer through 
lifestyle changes, in particular, with changes in the 
diet. The strong interrelationship between nutrition 
and occurrence of malignant tumors is well described 
in the literature [2, 3]. For instance, plant-rich diets 
may prevent 30–40% of all cancer types [2, 4–6]. This 
statement is supported by numerous epidemiological 
studies, which demonstrate that in Eastern countries, 
such as Japan, Vietnam, and Philippines, where people 
traditionally consume green tea and soy products, 
the incidence of breast cancer and prostate cancer 
is significantly lower than in other countries [7–14].
The prophylactic properties of green tea, soy pro-
ducts and various fruits and vegetables are attributed 
to the presence of components such as polyphenols. 
The polyphenols are a large and diverse group of com-
pounds contained in many plants and the antioxidant 
properties of polyphenols contribute to prevention of the 
diseases associated with oxidative stress, including can-
cer [15]. The ca techins, contained in tea leaf, flavonones 
in citrus plants, anthocyanidins and resveratrol from the 
peel and seeds of red grapes are especially rich sources 
of polyphenols.
Polyphenols, such as catechins in green tea, espe-
cially epi(-)gallocatechin-3-gallate and resveratrol of red 
grapes, effectively suppress the growth of human and 
animal cancer cells, in vitro. In particular, growth of lung, 
intestinal, colorectal or prostate cancer cells, as well 
as hepatoma or leukemia cells is inhibited by tea cat-
echins [16–18]. Studies in vivo have demonstrated that 
epi(-)gallocatechin-3-gallate in green tea and resveratrol 
in grapes have prophylactic properties and significantly 
reduce the yield of carcinogen-induced tumors in ex-
perimental animals [16, 19, 20]. Also, plant polyphenols 
inhibit the growth of different transplanted tumors in ani-
mals [20–25]. Further, the potential sy nergies between 
polyphenolic compounds in diverse diseases including 
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cancer [26], especially breast cancer [27], or liver can-
cer [28] are reported.
To evaluate the potential enhancement of antitumor 
activity of synthetic anticancer substances by plant 
polyphenols, we used chemotherapeutics widely ap-
plied in treatment of cancer, such as cisplatin, doxoru-
bicin, and cyclophosphamide, as well as synthetic inhibi-
tors of polyamine (PA) metabolism. Inhibitors of PA syn-
thesis are effective as antitumor substances, since PAs 
are absolutely necessary for the growth and proliferation 
of cells, including malignant cells [29–31]. Specific block-
ing of PA synthesis stops cell growth. At present time, 
inhibitors of PA metabolism are widely studied with aim 
of their further use as antitumor drugs [32, 33].
In present research, the extracts of green tea 
polyphenols containing five catechins (catechin, epi-
catechin, catechin gallate, epicatechin gallate and 
epi(-)gallocatechin-3-gallate) were used. Besides 
the extract of green tea, we have also studied antitu-
mor effect of bio-composites developed on the basis 
of extracts of green tea, red wine lees and lemon peel. 
In order to improve bioavailability of polyphenols, 
we also used the nanosized forms of the extracts. 
The pharmacological efficacy of the teas pulve rized 
into nanograde has been shown to be greatly en-
hanced [34]. This effect may be explained by the large 
increase of the absorbing area in fine nanotea particles 
and the tunnel effect allowing for quantum particles 
to overcome otherwise insurmountable ener gy barri-
ers. Quantum-mechanical tunneling highly increases 
the corresponding rate constant value, in such a way 
that catechins become able to trap the lipid peroxyl 
radicals competing with damaging free-radical chain-
lipid peroxidation [34].
The current research was aimed at the evaluation 
of the effects of plant polyphenols extracts derived 
from green tea, red wine lees and/or lemon peel alone 
and in combination with antitumor drugs on the growth 
and deve lopment of different transplanted experimental 
tumors.
MATERIALS AND METHODS
Preparation of green tea extract (GTE) and plant 
composites. Green tea leaves were purchased from 
a tea producer company (“Geoplant”, Tbilisi, Geor-
gia). Tea leaves were extracted with hot (80 °C) water 
(1:6 w/v) for 20 min under constant stirring; the water 
extract was filtered through “fine grade” filter sheet 
of “Vigo Sheet Filter” under pressure at a flow rate 
of 420 liters per hour. The filtrate was concentrated 
under vacuum to 15% dry matter, followed by spray 
drying in a lab scale Mini Spray Dryer Y015 (“Shanghai 
Pharmaceutical”, China). Inlet and outlet temperatures 
were 190 °C and 95 °C, respectively. Plant composites 
were produced from GTE, according to the patents 
of Georgia [35, 36]. Briefly, a GTE and red wine lees 
(GTRW) composite was prepared by mixing liquid red 
wine lees, produced from Georgian variety of Vitis 
 vinifera v. Saperavi, and dry powder of GTE. Wine lees 
were incubated overnight at 4 °C; after sedimentation, 
the supernatant was obtained by decantation and fil-
tered through a dense filter under vacuum. The filtered 
wine lees were heated on hot plate to 60 °C and dry GTE 
(1:2 v/v) was added gradually, with constant stirring 
and spray dried; the mixture was subsequently spray-
dried. The composites from GTE, red wine lees and 
lemon peels (GTRWL) were also prepared. The filtered 
supernatant of the red wine lees was poured into a ves-
sel containing pressed lemon peel (Georgian variety 
“Kartuli”), at a ratio of 6:1 v/w. The mixture was heated 
to 80 °C, held for 15 min and filtered through a dense 
filter under pressure. The filtered extract of red wine lees 
and lemon peel was added to GTE at a ratio of 1:2 based 
on dry matters content, filtered again through fine grade 
filter sheet and spray-dried. Plant extracts were further 
treated with 50% ethanol and the alcohol extract was 
centrifuged at 5,000 g, 10 min. The supernatant was 
collected and concentrated under vacuum. The extract 
was filtered under vacuum through 0.45 μm filters (“Pall 
Corporation”, USA). Dry powder was obtained by spray-
drying method. Nanoextracts were produced from 
ordinary plant extracts by reconstitution of dry powder 
into distilled water, filtration under vacuum through 
0.45 μm filters (“Pall Corporation”, USA) and spray 
drying. Bioactivity of nanoextracts is greatly enhanced 
because of increased absorbing area and quantum tun-
neling effect. An electron microscope (“Tesla BS-500”, 
Czech Republic) was used to estimate particle size.
Chemical analysis of tea extracts. Chemical 
analysis of plant materials and extracts was accom-
plished by the conventional procedures as described. 
The colorimetric assay using Folin — Ciocalteu reagent 
was used to determine the total polyphenol content 
in plant materials [37]. Pectic substances were quan-
titatively analyzed by the reaction of galacturonic acid 
with carbazole in sulphuric acid [38]. Amino acids were 
determined by colorimetric reaction of free amino acids 
with ninhydrin reagent with minor modifications [38]. 
For analysis of reducing sugars, the standard reducing-
sugar assay of Nelson and Somogyi was applied [40, 
41]. The content of organic acid was determined ac-
cording to ISO 750:1998 [42]. Total ash was determined 
according to ISO standard #7517–1990 (Instant tea 
in solid form — Determination of total ash) [43].
Experimental animals and care. Mice and rats 
were obtained from the vivarium of the R.E. Kavetsky 
Institute of Experimental Pathology, Oncology and 
Radiobiology of the NAS of Ukraine (IEPOR) and used 
in experiments. At the start of each experiment, the 
age of the animals was about 2–2.5 months; weight 
of animals was 20–24 g for mice and 120–150 g for rats. 
Species, strain and sex of animals varied depending 
on the tumor model of interest; specifics are reported 
in the description of experimental tumors. The animals 
of control and experimental groups were housed in plas-
tic cages with wire tops and maintained at the tempera-
ture of 22 °C, with a 12 h light–12 h dark cycle. In each 
group, 8–12 animals were used. The animals of control 
groups had standard lab diet (PK-120–4, Phoenix, Kyiv) 
and drank water ad libitum. The animals of experimen-
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tal groups had standard lab diet and drinking water 
containing 0.1% of indicated polyphenol extracts. All 
experiments on animals were carried out according 
to international requirements for work with experimental 
animals as described in: http://www.nc3rs.org.uk.
Experimental tumors. Tumor strains were ob-
tained from the Bank of Cell Lines from Human and 
Animal Tissues of R.E. Kavetsky IEPOR. The  following 
transplanted experimental tumors were used: sar-
coma S180 (transplanted to the non-inbred mice via 
s/c injection of 0.2 ml of 25% suspension of shred-
ded tissue per animal); Ehrlich carcinoma (solid form, 
transplanted to non-inbred mice via s/c injection 
of 106 tumor cells per animal); melanoma В16 (trans-
planted to С57Bl/6 mice via injection of 5•105 tumor 
cells in muscle of lower leg); Ca755 mammary car-
cinoma (transplanted to female С57Bl/6 mice via 
s/c injection of 0.2 ml of 20% suspension of shredded 
tissue); lymphocytic leukemia P388 and lymphocytic 
leukemia L1210 (transplanted to F1(C57Bl/6×DBA/2) 
BDF1 mice or F1(Balb/C×DBA/2) CDF1 mice via i/p in-
jection of 3–5•105 leukemia cells); Guerin carcinoma 
wild-type strain and its cisplatin- or doxorubicin-resistant 
variants generated and maintained in R.E. Kavetsky 
IEPOR. Guerin carcinoma was transplanted to non-
inbred female rats via s/c injection of 0.5 ml of 25% 
suspension of shredded tissue.
Animals were euthanized under the state of nar-
cosis and tumors were excised and weighed. Homo-
genates for biochemical studies were prepared from 
the liver, heart and kidneys.
Animals with ascitic tumors were guillotined and 
blood was collected. Thereafter, ascites were washed 
from the abdominal cavity with an isotonic solution 
of sodium chloride and the tumor cells were counted 
in the hemocytometer.
Administration of therapeutic agents. Polyphe-
nol extracts were dissolved in water, previously boiled 
and cooled to room temperature (near 20–22 °C). 
Since the second or third day after tumor transplan-
tation and until the end of experiment, animals in the 
treatment group received 0.1% solutions of plant ex-
tracts (GTE, GTRW, NanoGTE, NanoGTRW or NanoG-
TRWL) in the drinking water. Consumption by mice 
and rats  averaged 3–5 ml and 20–25 ml, respectively, 
per animal per day. Control animals with transplanted 
tumors received ordinary drinking water.
The following inhibitors of PA metabolism were 
used in the study: α-difluoromethylornithine (DFMO) — 
an inhibitor of ornithine decarboxylase (ODC); poly-
hexamethylenguanidin (PMG) — inhibitor of ODC 
and PA oxidase; methylglyoxal bis(guanylhydrazone) 
(MGBG) — inhibitor of S-adenosyl-L-methionine de-
carboxylase (S-AMDC) and also known as antitumor 
drug mitoguazone. DFMO and MGBG were purchased 
from the Aldrich (http://www.sigmaaldrich.com). PMG 
was kindly granted by a member of Latvia SA Marger 
Lidak (Institute of Organic Synthesis, Riga, Latvia).
In experiments, we have used the following an-
titumor drugs: Cisplatin and Doxorubicin (“Ebewe”, 
Austria), and Cyclophosphan (JSC “Kievmedpreparat”, 
Ukraine). Administration regimens and dosages are 
described in corresponding Table and Figure footnotes 
in Results.
To evaluate an effect of the GTE and GTE-
based composites on side toxicity of anticancer 
drugs, creatinine and urea contents in blood serum 
were measured using standard kits according to the 
manufacturer’s recommendations (Felicit Diagnostica, 
Dnepropetrovsk, Ukraine); malondialdehyde (MDA) 
in tissues was measured as described by Stalnaya and 
Garishvili [44]; blood cells were counted in hemocy-
tometer. Blood was treated with heparin and diluted 
1:20 with 3% solution of concentrated acetic acid in sa-
line to count leucocytes or diluted 1:400 in saline alone 
to count erythrocytes. Blood serum for biochemical 
studies has been prepared by standard method.
Statistical analysis of the results was  conducted [45]. 
For the evaluation of significance of differences be-
tween groups, the Student’s t-test was used. Significant 
differences were set at p < 0.05. The data in Figures and 
Tables are presented as M ± m.
RESULTS
Chemical composition and particle size of the 
extracts. The chemical composition of the extracts 
is presented in Table 1. The extracts contain polyphe-
nols as well as pectin, amino acids, organic acids, and 
mineral elements. The total phenolic composition for 
the extracts ranged from 18.0 to 21.3 g/100 g and was 
nearly the same for all extracts regardless of the treat-
ment. A wider variation was observed in the total sugars, 
which ranged from 20.2 to 30.0 g/100 g. There was 
a lesser amount of pectic substances, organic acids 
and amino acids in the tea extracts and composites (see 
Table 1). Total ash was less than 8 g/100 g in all samples.
Table 1. Chemical composition of green tea, wine, lemon peel extracts
Sample Poly-phe-nolics
Reducing 
sugars
Pectic sub-
stances
Organic 
acids
Amino 
acids Total ash
GTE 20.1 ± 0.5 28.0 ± 0.9 10.0 ± 0.8 10.8 ± 0.4 7.5 ± 0.3 8.0 ± 0.4
NanoGTE 20.0 ± 0.6 27.5 ± 0.9 10.0 ± 0.8 9.0 ± 0.4 7.3 ± 0.4 8.3 ± 0.4
GTRW 18.2 ± 0.5 30.0 ± 0.8 10.3 ± 0.5 9.5 ± 0.4 10.3 ± 0.4 8.2 ± 0.5
NanoGTRW 20.5 ± 0.7 29.5 ± 0.9 9.8 ± 0.5 8.5 ± 0.4 10.0 ± 0.3 8.4 ± 0.4
GTRWL 21.3 ± 0.8 20.2 ± 0.7 13.0 ± 0.7 13.9 ± 0.5 7.0 ± 0.4 8.0 ± 0.3
NanoGTRWL 18.0 ± 0.5 22.5 ± 0.6 12.5 ± 0.8 9.0 ± 0.3 7.3 ± 0.5 8.2 ± 0.4
Note: Units are g/100g. Data are presented as a mean of three measure-
ments ± standard deviation. Green tea extract (GTE); GTE with particle size 
of 10–45 nm (NanoGRE); composite of NanoGTE and red wine phenolics 
(NanoGTRW); composite of GTRW and lemon peel phenolics (GTRWL); com-
posite of NanoGTRW and lemon peel phenolics (NanoGTRWL).
Particle size of nanoextacts under electronic mi-
croscope was between 10–45 nm.
Antitumor effect in mice. The antitumor properties 
of polyphenolic extracts and biocomposites were tested 
in murine transplanted tumors: sarcoma 180, solid Ehr-
lich carcinoma, Са755 mammary carcinoma, В16 mela-
noma, P388 lymphocytic leukemia, and L1210 lymphoid 
leukemia. NanoGTE suppressed the growth of sarcoma 
180 by 27%, compared to 55% inhibition of growth by cis-
platin. It is important to emphasize that use of NanoGTE 
in combination with cisplatin increased tumor growth 
inhibition (TGI) up to 78% (Table 2).
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Table 2. TGI effect of NanoGTE, cisplatin and their combined application 
in mouse sarcoma 180
Group No. animals per group Tumor mass, g TGI, %
Control 10 3.70 ± 0.20 —
NanoGTE 10 2.70 ± 0.20* 27
Cisplatin 10 1.66 ± 0.16** 55
Cisplatin + NanoGTE 10 0.80 ± 0.13**;*** 78
Note: Analysis was conducted on 21st day after tumor transplantation. 
NanoGTE was administered as 0.1% solution in drinking water on the third 
day after tumor transplantation. Cisplatin was administered as 5 i/p injections 
(1.2 mg/kg), once per two days, starting from 10th day after tumor transplan-
tation (*p < 0.01; **p < 0.001 as compared to control; ***p < 0.001 as com-
pared to cisplatin).
Similar results were obtained for solid Ehrlich car-
cinoma (Table 3). TGI was 21%, 45% and 59% in mice 
treated with NanoGTE, сisplatin, or their combination, 
respectively. Also, the absolute tumor weight reduction 
and percentage inhibition, showed an enhancement 
of сisplatin effect by NanoGTE.
Table 3. TGI effect of NanoGTE, cisplatin and their combined applica-
tion in solid Ehrlich carcinoma in mice
Group No. animals per group Tumor mass, g TGI, %
Control 10 2.90 ± 0.20 —
NanoGTE 8 2.30 ± 0.13* 21
Cisplatin 8 1.60 ± 0.12** 45
Cisplatin + NanoGTE 8 1.22 ± 0.11**;*** 59
Note: Analysis was conducted on 21st day after tumor transplantation. 
NanoGTE and cisplatin were administered as described in Table 2. *p < 0.05; 
**p < 0.001 as compared to control; ***p < 0.001 as compared to cisplatin.
NanoGTE, NanoGTRW, and NanoGTRWL showed 
TGI (Fig. 1). On the 24th day after B16 transplantation 
in animals treated with NanoGTE, NanoGTRW, and 
NanoGTRWL the tumor weight was 3.51 ± 0.39; 3.34 ± 
0.65, and 2.36 ± 0.57 g, respectively. Relative to the 
control value of 3.82 ± 0.39 g, this represents an in-
hibition rate of 8%, 12%, and 38%, respectively. The 
inhibition by the NanoGTRWL extract was statistically 
significant (p < 0.05). The results evidence on synergis-
tic B16-suppressing effect of red wine lees and lemon 
peel polyphenols included to the GTE.
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Fig. 1. TGI effects of NanoGTЕ, NanoGTRW and NanoGTRWL 
in mouse melanoma B16. Plants extracts were administered 
as 0.1% solutions in the drinking water. Tumor mass was mea-
sured on 24th day after tumor transplantation. Note: *Significantly 
different from the control (p < 0.05).
Cyclophosphamide, NanoGTRWL, or their combi-
nation resulted in slower growth of Ca755 carcinoma 
in С57Bl/6 female mice (Fig. 2) and lower tumor weight 
on 23rd day after Ca755 transplantation (Fig. 3). At this 
time point, the average tumor weight was 2.59 ± 0.29; 
0.98 ± 0.26; 1.65±0.45 g, in the control, cyclophos-
phamide-, and NanoGTRWL-administered groups, 
respectively. Treatment with cyclophosphamide and 
NanoGTRWL reduced the tumor weight by 62 or 36%, 
respectively, compared to the control. Administration 
of NanoGTRWL and cyclophosphamide combination 
led to the most effective reduction of tumor weight 
up to 0.67 ± 0.32 g (by 74% vs. control group; see 
Fig. 3). The cyclophosphamide-dependent inhibition 
was significantly enhanced by NanoGTRWL. Moreover, 
treatment with NanoGTRWL prolonged the lifespan 
of Ca755-bearing animals: on the 23rd day after 
Ca755 transplantation all animals in NanoGTRW-tre-
ated group were alive vs. 33% in the control group.
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Fig. 2. TGI effects of cyclophosphamide, NanoGTRWL and their 
combined application in Ca755 mammary carcinoma growth 
dynamics in С57Bl/6 female mice.  NanoGTRWL was adminis-
tered as 0.1% solution in the drinking water. Cyclophosphamide 
was administered intraperitoneally (i/p): 45 mg/kg, 5 injections 
(on the 14th, 15th, 17th,18th and 20th days after tumor transplanta-
tion) 
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Fig. 3. TGI effects of cyclophosphamide, NanoGTRWL and 
their combined application in Ca755 mammary carcinoma 
in С57Bl/6 female mice. NanoGTRWL was administered as 0.1% 
solution in the drinking water. Cyclophosphamide was admini-
stered intraperitoneally (i/p): 45 mg/kg, 5 injections (on the 
14th, 15th, 17th,18th and 20th days after tumor transplantation; 
tumor mass was measured at 23rd day after transplanta-
tion). Note: *p < 0.001 as compared to the control animals; 
**0.05 < p < 0.08 (NanoGTRWL + cyclophosphamide group 
as compared to the GTRWL group); ***0.1 < p  < 0.2 ( NanoGTRWL 
+ cyclophosphamide group as compared to the cyclophospha-
mide  group)
In another series of experiments, we have stu died 
effects of NanoGTE and NanoGTRW and their com-
bination with inhibitors of PA metabolism — DFMO, 
MGBG, PMG on the growth of lymphocytic leukemia 
P388 and lymphoid leukemia L1210 in mice. The results 
are shown in Fig. 4–6. The PA synthesis inhibitors and 
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NanoGTE suppressed the growth of P388 lymphocytic 
leukemia in mice (see Fig. 4). The tumor cells count 
was reduced by 11%, 27%, or 39% when NanoGTE, 
DFMO + MGBG or PMG were admini stered. However, 
when the combination of DFMO, MGBG and NanoGTE 
was administered, the count of tumor cells decreased 
by 58%. When the combination of PMG and NanoGTE was 
administered, the tumor cell count decreased by 50% reia-
tive to control and by 40% as compared to PMG treatment 
only. The combined application of NanoGTE and inhibitors 
of PA synthesis was the most effective in inhibiting growth 
of transplantable leukemia.
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Fig. 4. TGI effects of NanoGTE, α-DFMO + MGBG, PMG and their 
combined application in P388 leukemia in СDF1 mice. P388 leu-
kemia cells (5•105 cells per mouse) were transplanted; NanoGTE 
was administered as 0.1% solution in the drinking water, α-DFMO — 
800 mg/kg (3 injections), MGBG — 10 mg/kg (3 injections), and 
PMG — 1.5 mg/kg (3 injections);  the number of P388 leukemia 
cells was counted on the 7th day after P388 transplantation). Note: 
*p < 0.1; **p < 0.001 as compared to the control animals
In addition, the combined effect of DFMO + MGBG 
and NanoGTE exceeded the sum of their individual 
effects. The differences between DFMO + MGBG 
+ NanoGTE group and DFMO + MGBG group, or between 
DFMO + MGBG + NanoGTE group and NanoGTE group 
were statistically significant (p < 0.05 and p < 0.005).
In contrast, the joint effect of PMG and NanoGTE 
was lower than the sum of their individual effects: 
0.05 < p < 0.1 for PMG + NanoGTE group vs. PMG group; 
p < 0.005 for PMG + NanoGTE vs. NanoGTE group.
In animals with transplanted P388 leukemia cells, 
similar TGI was observed in the cases of combined 
application of PMG and NanoGTE or PMG and NanoG-
TRW (see Fig. 5) or combined application of DFMO, 
MGBG with NanoGTE (see Fig. 6). The synergistic 
effect of PMG and NanoGTE or PMG and NanoGTRW 
combination is illustrated by the p values where 0.1 < 
p < 0.2 — control group vs. PMG group; p < 0.005 — 
control group vs. PMG + NanoGTE group; p < 0.005 — 
control group vs. PMG + NanoGTRW group (TGI was 
26.5%, 54%, and 57% in PMG, PMG + NanoGTE, and 
PMG + NanoGTRW-treated animals, respectively). 
The diffe rences between DFMO + MGBG + NanoGTE 
and DFMO + MGBG groups were significant (p < 0.05) 
as well as between DFMO + MGBG + NanoGTE 
and NanoGTE groups (p < 0.02) and demonstrated 
an enhancement of DFMO + MGBG antitumor effects 
by NanoGTE (see Fig. 6).
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Fig. 5. TGI effects of PMG and combined application of PMG 
with NanoGTE or PMG with NanoGTRW in P388 leukemia 
in СDF1 mice. P388 leukemia cells (3•105 cells per mouse) 
were transplanted; NanoGTE and NanoGTRW were administered 
as 0.1% solutions in the drinking water; PMG — 1.5 mg/kg 
(3 injections); the number of P388 cells was counted on the 7th 
day after P388 transplantation). Note: *p < 0.001 as compared 
to the control animals; **p < 0.01 and ***p  < 0.001 as compared 
to the PMG group
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Fig. 6. TGI effects of NanoGTE, α-DFMO + MGBG and their com-
bined application on P388 leukemia in СDF1 mice (5•105 tumor 
cells transplanted per mouse; NanoGTE administered as 0.1% 
solution in the drinking water; α-DFMO was administered 
at 800 mg/kg (4 injections); MGBG — 10 mg/kg (4 injections); the 
number of cells was counted 7 days after transplantation). Note: 
*p < 0.05; **p < 0.01; ***p < 0.001 as compared to the control 
animals; +p < 0.05 compared to the α-DFMO + MGBG group 
The influence of NanoGTE, NanoGTRW and their 
combination with inhibitors of PA metabolism (DFMO, 
MGBG and PMG) on the growth of L1210 lymphoid leu-
kemia in mice, is presented in Fig. 7, 8 and Table 4. 12% 
decrease in leukemic cell count in NanoGTE-treated 
CDF1 mice was observed. Higher inhibition (by 28%) was 
observed after 3 injections of α-DFMO (800 mg/kg) and 
MGBG (10 mg/kg) (see Fig. 7). In the case of combined 
application of α-DFMO + MGBG + NanoGTE, decrease 
in leukemia cell count in mice was 30%, and the com-
bined application of α-DFMO + MGBG + NanoGTRW 
resulted in 54% of reduction of cell count. Significant 
enhancement of the antitumor effect was observed in the 
case of NanoGTRW + α-DFMO + MGBG (p < 0.001) 
(see Fig. 7) and PMG + NanoGTRW (p < 0.02) (Fig. 8). 
Likewise, an increased antitumor effect of NanoGTE and 
synthetic inhibitors of the PA metabolism was observed 
in BDF1 mice transplanted with L1210 leukemia (see 
Table 4). The statistical analysis (p < 0.02 for DFMO 
+ MGBG + NanoGTE group vs. DFMO + MGBG group; 
p < 0.0005 for DFMO + MGBG + NanoGTE group vs. 
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NanoGTE group) showed that the combined application 
of NanoGTE with the inhibitors of PA metabolism signifi-
cantly enhances antitumor effect.
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Fig. 7. TGI effects of NanoGTE, α-DFMO + MGBG and com-
bined application of α-DFMO + MGBG with NanoGTE and 
NanoGTRW on L1210 leukemia in СDF1 mice. L1210 leukemia 
cells (5•105 cells per mouse) were transplanted; NanoGTE and 
NanoGTRW were administered as 0.1% solutions in the drinking 
water; α-DFMO — 800 mg/kg (3 injections); MGBG — 10 mg/kg 
(3 injections); the number of L1210 cells was counted on 10th 
day after L1210 transplantation. Note: *p < 0.001 as compared 
to the control animals; **p < 0.001 as compared to the α-DFMO 
+ MGBG group
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Fig. 8. TGI effects of NanoGTRW, PMG and their combined ap-
plication on L1210 leukemia in СDF1 mice. L1210 leukemia cells 
(5•105 cells per mouse) were transplanted; NanoGTRW was 
administered as 0.1% solution; PMG — by 1.5 mg/kg in 5 injec-
tions; the number of L1210 cells was counted on 11th day after 
L1210 transplantation. Note: *p < 0.1; **p < 0.02 as compared 
to the control animals
Table 4. TGI effect of DFMO + MGBG, NanoGTE and their combined ap-
plication in BDF mice with L1210 leukemia
Group of animals No. animals per group
Cell number, 
×108 cells/animal TGI, %
Control 12 15.5 ± 1.4 —
DFMO + MGBG 9 7.8 ± 0.5* 50
NanoGTE 9 13.1 ± 0.8 15
DFMO + MGBG + NanoGTE 9 4.2 ± 1.5*, ** 73
Note: Analysis was conducted on 12th days after L1210 transplantation 
(5•105 cells per BDF1 mouse). DFMO (800 mg/kg) and MGBG (10 mg/kg) 
were administered as 5 i/p injections each (*p < 0.001 compared to the con-
trol; **p < 0.05 as compared to α-DFMO + MGBG effect)
Similar results have been obtained in the case 
of combined application of NanoGTRW and another 
inhibitor of PA metabolism, PMG (see Fig. 8). The com-
bined application of PMG and NanoGTRW resulted 
in 48% decrease in leukemic cell number. In summary, 
the results indicate that polyphenol extracts alone 
manifest growth-inhibiting effect in relation to lym-
phoid leukemia L1210 and P388, with their eﬀ ect being 
signiﬁ cantly enhanced in combination with inhibitors 
of PA biosynthesis.
Antitumor effect in rats. The antitumor activity 
of polyphenol extracts (GTE and GTRW) was studied 
in rats transplanted with wild-type Guerin carcinoma 
(Tables 5, 6) and its cisplatin- and doxorubicin-
resistant variants (Fig. 9, 10). Consumption of 0.1% 
solutions of GTE (see Table 5) or GTRW (see Table 6) 
by animals caused the Guerin carcinoma growth inhibi-
tion by 28 and 25%, correspondingly. The combined 
treatment with GTE or GTRW with cisplatin increased 
antitumor effect of cisplatin used alone.
Table 5. TGI effect of cisplatin, GTE and their combined application 
in parental strain of Guerin carcinoma
Group of animals No. of animals per group Tumor weigh, g TGI, %
Control 7 25.8 ± 3.1 —
GTE 5 18.7 ± 5.6 28
Cisplatin 5 11.6 ± 1,0* 55
GTE + cisplatin 5 3.04 ± 0.9**, *** 88
Note: Analysis was conducted on 16th day after transplantation of Guerin 
carcinoma. Cisplatin was administered in 5 i/p injections (1.2 mg/kg), eve-
ry other day, starting from 10th day after tumor transplantation; GTE was ad-
ministered as 0.1% in drinking water. *p < 0.01; **p < 0.001 as compared 
to the control; *** p < 0.0005 — GTE + сisplatin as compared to the cispla tin; 
p < 0.0005 — GTE + сisplatin as compared to the GTE
Table 6. TGI effect of cisplatin, GTRW and their combined application 
in parental strain of Guerin carcinoma
Group of animals No. of animals per group Tumor weight, g TGI, %
Control 7 45.4±3.1 —
GTRW 7 34.0±3.6* 25
Cisplatin 7 14.7±4.0** 68
Cisplatin + GTRW 7 8.6±1.1**; *** 81
Note: Analysis was conducted on19th day after transplantation of Guerin 
carcinoma. Cisplatin and GTRW were administered as described in Table 5. 
*p < 0.05; **p < 0.001 as compared to the control; ***p < 0.1 as compared 
to the cisplatin-treated group.
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Fig. 9. TGI effects of cisplatin, GTE, NanoGTE and their com-
bined application on cisplatin-resistant Guerin carcinoma in rats. 
GTE, NanoGTE were administered as 0.1% solutions; cisplatin 
was administered via 5 i/p injections by 1.2 mg/kg; the tumor 
mass was measured on 21st day after tumor transplantation. 
Note: *p < 0.01; **p < 0.001; ***p < 0.001; as compared 
to the control animals; +p < 0.02 as compared to the сisplatin 
group; p < 0.01 when GTE + сisplatin group to the сisplatin 
group; p ≈ 0.1 when GTE + сisplatin group to the GTE group; 
p < 0.01 when NanoGTE + сisplatin group was compared to the 
сisplatin group; p < 0.01 when NanoGTE + сisplatin group was 
compared to the NanoGTE group
The effects of GTE and NanoGTE, or their combi-
nation with cisplatin (see Fig. 9) or doxorubicin (see 
Fig. 10) were evaluated in drug-resistant variants 
of Guerin carcinoma. When rats were treated with cis-
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platin or consumed 0.1% solutions of GTE or  NanoGTE, 
the decrease of tumor weight was not significant (by 11%, 
17%, and 22%, correspondingly, p > 0.05). When cisplatin 
and GTE were administered in combination, TGI reached 
30% (p < 0.01). The highest growth inhibition of cisplatin-
resistant Guerin carcinoma was observed in rats treated 
with cisplatin with NanoGTE (p < 0.001); the TGI index 
in this case was 65% (see Fig. 9).
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Fig. 10. TGI effects of doxorubicin, GTE, NanoGTE and their 
combined application on doxorubicin-resistant Guerin’s carcino-
ma in rats. GTE, NanoGTE were administered as 0.1% solutions; 
doxorubicin was admini stered via 4 i/p injections by 1.5 mg/kg; 
the tumor mass was measured on 17th day after tumor transplan-
tation. Note: *p < 0.05; **p < 0.001 as compared to the control 
animals; ***p < 0.001; +p>0.1 as compared to the doxorubicin 
group; 0.05 < p < 0.1 when doxorubicin + GTE group was com-
pared to the doxorubicin group; 0.1 < p < 0.25 when doxorubicin 
+ GTE group was compared to the GTE group; p < 0.005 when 
doxorubicin + NanoGTE group was compared to the doxorubicin 
group; p < 0.05 when doxorubicin + NanoGTE group was com-
pared to the NanoGTE group
In the case of administration of doxorubicin and 
GTE, TGI was 18 and 22%, without significant differ-
ence from the control (p > 0.05) (see Fig. 10). Admini-
stration of NanoGTE or GTE and doxorubicin reduced 
tumor weight by 34% (p < 0.05) and 32% (p < 0.05), 
respectively. As single agents, neither doxorubicin, 
nor GTE had a significant effect on tumor weight. 
The highest TGI (57%; p < 0.001) was observed in the 
case of the combined application of doxorubicin and 
NanoGTE. The results demonstrate that consumption 
of 0.1% solution of GTE (and especially NanoGTE) 
increased therapeutic activity of cisplatin and doxo-
rubicin in chemoresistant Guerin carcinoma variants.
Anti-toxic properties of tea extracts. In can-
cer therapy with drugs like doxorubicin or cisplatin, 
an increase in MDA, urea or creatinine as well as the 
changes in blood count (increased leukocyte and re-
duced erythrocyte counts, hemoglobin and platelets) 
are indicative of their adverse effects. The potential 
of plant extracts and composites to reduce toxicity 
associated with doxorubicin and cisplatin was of par-
ticular interest.
Therefore, changes in MDA content in tissues 
of heart (Fig. 11), liver (Fig. 12, 13), and kidneys 
(Fig. 14) of rats were evaluated. Tissue MDA levels were 
higher in animals after tumor transplantation and after 
chemotherapy while the plant extracts and composites 
diminished this effect. In rats with doxorubicin-resis-
tant Guerin carcinoma, MDA levels in control rats and 
untreated rats were 2.7 and 5.9 μM/g of heart tissue 
respectively, and increased up to 6.3 μM/g of heart 
tissue in animals treated with doxorubucin. Admi-
nistration of GTE, NanoGTE, doxorubicin and GTE 
or doxorubicin and NanoGTE, significantly decreased 
(p < 0.001) MDA level (see Fig. 11).
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Fig. 11. Effect of GTE, NanoGTE, doxorubicin and their combina-
tion on heart MDA level in the animals with grafted doxorubicin-
resistant Guerin carcinoma. Note: *p < 0.001 as compared to the 
untreated and doxorubicin-treated rats
In rats with doxorubicin-resistant Guerin carci-
noma, MDA levels in control rats and untreated rats 
were 1.7 and 3.0 μM/g liver tissue, respectively, and 
increased up to 3.2 μM/g liver tissue in animals treated 
with doxorubucin. Administration of GTE, NanoGTE, 
doxorubicin and GTE or doxorubicin and NanoGTE, 
significantly decreased (p < 0.001) MDA level (Fig. 12).
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Fig. 12. Effect of GTE, NanoGTE, doxorubicin and their combina-
tion on liver MDA level in the animals with doxorubicin-resistant 
Guerin carcinoma. Note: *p < 0.001 as compared to the intact 
animals; **p < 0.001 as compared to the untreated and doxo-
rubicin-treated animals
In rats with cisplatin-resistant Guerin carcinoma, 
MDA levels in control rats and untreated rats were 
1.7 and 2.6 μM/g liver tissue, respectively, and in-
creased up to 2.7 μM/g liver tissue in animals treated 
with cisplatin. Administration of GTE significantly de-
creased (p < 0.001) the level of MDA to 1.8 μM/g liver 
tissue (Fig. 13).
In rats with cisplatin-resistant Guerin carcinoma, 
MDA levels in kidneys of control rats and untreated rats 
were 7.3 and 8.0 μM/g liver tissue, respectively, and 
increased to 9.5 μM/g liver tissue in animals treated 
with cisplatin. Administration of GTE significantly de-
creased (p < 0.001) the level of MDA to 7.1 μM/g kid-
ney tissue (Fig. 14).
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The urea and creatinine levels in blood serum 
of Sarcoma 180-bearing mice and solid Ehrlich carci-
noma-bearing mice after administration of NanoGTE 
and cisplatin were also studied. Cisplatin adminis-
tration increased blood serum urea and creatinine 
content by 37 and 31%, respectively. NanoGTE 
in combined therapy decreased the level of urea and 
creatinine by approximately 13 and 11%, respectively, 
as compared to cisplatin (Table 7). The urea and creati-
nine levels in blood serum of solid Ehrlich carcinoma-
bearing mice after administration of NanoGTE and cis-
platin were studied. Cisplatin administration resulted 
in an increase of blood serum urea and creatinine 
content by 43 and 41%, respectively. The NanoGTE use 
in combined therapy decreased the level of urea and 
creatinine practically to the control values (Table 8).
Some of the plant extracts and composites improved 
the peripheral blood values (Table 9), especially they 
increased erythrocyte and platelet counts, hemoglobin 
content and decreased leukocyte counts. In mice with 
L1210 leukemia treated with NanoGTE or NanoGTE, 
DFMO and MGBG, leukocyte counts were reduced from 
30.5•103/ml to 17.8•103/ml. Notably, platelet counts 
increased (p < 0.05) in mice that received NanoGTE, 
NanoGTRW, or composites of these plant extracts with 
DFMO and MGBG. Platelet counts increased from 
260•103/ml to a range of 438–594•103/ml, depending 
on extract (see Table 9). In mice with P388 lymphocytic 
leukemia, leukocytes decreased significantly (p < 0.01) 
from 65 to 24 or 33•103/ml when treated with NanoGTE, 
NanoGTRW or composites (Table 10). Also, hemoglobin 
content increased significantly (p < 0.01) in mice treated 
with NanoGTE (see Table 10).
Table 7. Levels of urea and creatinine in blood serum of sarcoma 180-be-
aring mice after administration of NanoGTE, cisplatin and their combination
Group of animals, n Urea level, mmol/l Creatinine, μmol/l
Control, n = 10 7.14 ± 0.28 71.07 ± 2.26
NanoGTE, n = 10 7.34 ± 0.31 70.00 ± 2.11
Cisplatin, n = 10 9.80 ± 0.23* 92.96 ± 3.12*
Cisplatin + NanoGTE, n = 10 8.56 ± 0.47** 82.41 ± 2.47***
Note: *p < 0.001 as compared to the control; **p < 0.05; ***p < 0.02 as com-
pared to the cisplatin-treated group.
Table 8. Levels of urea and creatinine in blood serum of solid Ehrlich carcinoma-
bearing mice after administration of NanoGTE, cisplatin and their combination
Group of animals, n Urea, mmol/l Creatinine, μmol/l
Control, n = 10 7.2 ± 0.2 71.3 ± 1.8
NanoGTE, 0.1% solution, n = 10 7.2 ± 0.2 70.0 ± 2.3
Cisplatin, n = 10 10.3 ± 0.5* 100.3 ± 3.6*
Cisplatin + NanoGTE, 0.1% so-
lution, n = 10 7.6 ± 0.4** 73.7 ± 3.4***
Note: *p < 0.001 as compared to the control; **p < 0.01; ***p < 0.001 as com-
pared to the cisplatin-treated group.
Table 9. Some hematological parameters in mice with L1210 leukemia after ad-
ministration of NanoGTE, NanoGTRW, DFMO + MGBG and their combinations
Group of animals, n
Leuko-
cytes, 
×103/ml
Eryth-
rocytes, 
×106/ml
Hemoglo-
bin, g/dl
Platelets, 
×103/ml
Control animals with 
L1210, n = 5 30.5 ± 5.2 8.2 ± 2.8 15.6 ± 1.1 260.3 ± 22.6
NanoGTE, n = 5 17.8 ± 1.7* 10.6 ± 0.4 16.3 ± 1.2 544.3 ± 18.8**
NanoGTRW, n = 5 23.5 ± 4.0 11.7 ± 1.2 17.0 ± 1.1 594.6 ± 10.1**
DFMO + MGBG + 
NanoGTE, n = 5 18.4 ± 1.0* 10.4 ±0.5 15.8 ± 1.1 485.0 ± 8.1**
DFMO + MGBG, n = 5 17.1 ± 3.9 13.0 ± 0.5 19.5 ± 0.3* 305.3 ± 32.8
DFMO + MGBG + 
NanoGTRW, n = 5 22.5 ± 4.4 11.2 ± 0.8 16.3 ± 1.0 438.6 ± 9.3**
Note: *p < 0.05; **p < 0.001 as compared to the control.
Table 10. Some hematological parameters in mice with Р388 leukemia af-
ter administration of NanoGTE, DFMO + MGBG and their combinations
Group of ani-
mals, n 
Leukocytes, 
×103/ml
Erythro-
cytes, 
×106/ml
Hemoglobin, 
g/dl
Platelets, 
×103/ml
Control animals 
with Р388, n = 5 65.2 ± 5.6 6.5 ± 1.10 9.1 ± 0.35 326.0 ± 29.0
NanoGTE, n = 5 54.5 ± 9.8 8.6 ± 0.1 10.7 ± 0.25** 343.0 ± 20.1
DFMO + MGBG, 
n = 5 33.2 ± 7.0** 9.5 ± 0.6* 12.5 ± 0.8** 424.3 ± 45.8
DFMO + MGBG + 
NanoGTE, n = 5 23.9 ± 4,6*** 9.4 ± 1.1 11.5 ± 1.2 339.3 ± 32.4
DFMO + MGBG + 
NanoGTRW, n = 5 25.9 ± 5.0*** 9.5 ± 0.6* 12.1 ± 0.6** 358.3 ± 37.7
Note: *p < 0.05; **p < 0.01; ***p < 0.001 compared to the control.
DISCUSSION
The results of this study support the observation 
that plant polyphenolic extracts derived from green tea 
possess antitumor activity. Our results are in a good 
agreement with similar in vivo data obtained by other 
authors [20, 28, 32].
Furthermore, the favorable influence of GTE was 
observed regardless of cancer cell type evaluated. 
Moreover, composites with green tea and red wine 
lees and/or lemon peel green tea (NanoGTRW and 
NanoGTRWL) manifest antitumor activity and suppress 
growth of solid and ascitic tumors in experimental 
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animals. GTE and composites of GTE with particle 
size less than 45 nm were also effective. This study 
documents that NanoGTE and NanoGTRW enhance 
the antitumor activity of doxorubicin, cisplatin and 
inhibitors of PA synthesis.
Particularly for drug-resistant experimental tumors, 
the synergism of doxorubicin or cisplatin with plant 
extracts is reflected in an enhanced efficacy of chemo-
therapy. Further impact of the beneficial effect of plant 
extract in cancer therapy is a decrease of some indices 
of doxorubicin-related cardiotoxicity and cisplatin-
related nephrotoxicity. Plant extracts decrease the 
levels of creatinine and urea in blood serum, decrease 
the levels of MDA in tissues of heart, kidneys and liver 
of animals with transplanted tumors. Finally, some of the 
plant extracts increase the lifespan [22] and improve he-
matological values in animals with experimental tumors.
So, the results demonstrate that extracts and 
nanoextracts of green tea (GTE and NanoGTE) and 
corresponding composites (GTRW, GTRWL and their 
nanosized modifications) themselves essentially retard 
growth of different experimental tumors. Moreover, 
these agents enhance therapeutic activity of cisplatin 
and doxorubicin in different experimental tumor mo-
dels, especially in drug-resistant ones. Therefore, the 
obtained data indicate the prospects of further deve-
lopment of GTE and corresponding nanocomposites 
as auxiliary agents in cancer chemotherapy.
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